The Effect of Multimodal Treatment of Rectal Cancer on Circulating Tumor Cells: A Prospective, Observational Study
NCT ID: NCT07112937
Last Updated: 2025-08-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
150 participants
OBSERVATIONAL
2023-05-02
2027-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The CTCs levels will be compared among rectal cancer patients with neoadjuvant chemoradiotherapy and without neoadjuvant chemotherapy.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Rectal Cancer CTC Trial
NCT07194616
Prospective Assessment of Symptoms and Quality of Life in Rectal Cancer Patients Receiving Chemo-Radiotherapy
NCT00414232
Detection and Enumeration of Circulating Tumor Cells in Rectal Cancer
NCT01671891
Preoperative Chemoradiation With Capecitabine and Cetuximab
NCT00297128
Neoadjuvant Treatment of Fruquintinib Combined With Concurrent Chemoradiotherapy for LARC
NCT05575635
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Rectal cancer patients with neoadjuvant chemoradiotherapy
No interventions assigned to this group
Rectal cancer patients without neoadjuvant chemoradiotherapy
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
The Institute of Molecular and Translational Medicine, Czech Republic
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Hospital Ostrava
Ostrava, , Czechia
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Ihnat P, Srovnal J, Hrubovcak J, Martinek L. Detection and clinical significance of circulating tumour cells in patients with colorectal carcinoma. Rozhl Chir. 2023;102(10):376-380. doi: 10.33699/PIS.2023.102.10.376-380.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
LF_2023_0118
Identifier Type: OTHER
Identifier Source: secondary_id
01/RVO-FNOs/2023
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.